BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients
August 22 2023 - 05:08PM
Dow Jones News
By Stephen Nakrosis
Bristol Myers Squibb said Tuesday it had received European
Commission approval for Opdivo as an adjutant treatment for certain
melanoma patients.
Opdivo, or nivolumab, was approved to treat patients with
completely resected stage IIB or IIC melanoma.
The approval covers all European Union member states, as well as
Iceland, Liechtenstein, and Norway, the company said.
Opdivo is the only PD-1 inhibitor indicated as an adjuvant
treatment within stages IIB, IIC, III, as well as stage IV resected
melanoma. The treatment is designed to harness the body's own
immune system to help restore anti-tumor immune response, the
company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 22, 2023 16:53 ET (20:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Oct 2023 to Nov 2023
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Nov 2022 to Nov 2023
